`Patent No. 7,157,456
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS, INC.
`Petitioner,
`
`v.
`BAYER INTELLECTUAL PROPERTY, GMBH,
`Patent Owner.
`
`
`
`Case No. IPR2017-00041
`Patent No. 7,157,456
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8(a)(2)
`
`
`Patent Owner Bayer Intellectual Property GmbH hereby submits the
`
`
`
`following mandatory notices pursuant to 37 C.F.R. § 42.8(a)(2).
`
`A. Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1))
`
`Pursuant to 37 C.F.R. § 42.8(b)(1), Patent Owner identifies Bayer
`
`Intellectual Property GmbH (the Patent Owner), Bayer Pharma AG (an exclusive
`
`licensee), and Janssen Pharmaceuticals, Inc. (an exclusive sublicensee).
`
`In addition, out of an abundance of caution, the Patent Owner notes that
`
`counsel for Bayer Corporation has been involved in this proceeding, and further
`
`notes that each of Bayer Intellectual Property GmbH, Bayer Pharma AG, and
`
`
`
`
`
`
`Bayer Corporation is a wholly owned subsidiary of Bayer AG, and that Janssen
`
`Case IPR2017-00041
`Patent No. 7,157,456
`
`Pharmaceuticals, Inc. is a wholly-owned subsidiary of Johnson & Johnson.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2))
`
`The Patent Owner identifies the following matters that may affect, or may be
`
`affected by, a decision in this proceeding:
`
` Bayer Intellectual Property GmbH v. Aurobindo Pharma Ltd., No.
`1:15-cv-902-SLR (D. Del), a proceeding in which Patent Owner has
`asserted U.S. Patent No. 7,157,456 (“the ’456 patent”), related U.S.
`Patent No. 7,592,339 (“the ’339 patent”) and related U.S. Patent No.
`7,585,860 (“the ’860 patent”) against Petitioner and other defendants.
`Two other cases in which Bayer has asserted the ’456 patent have
`been consolidated with Case No. 15-cv-902-SLR: (1) Bayer
`Intellectual Property GmbH, et al. v. Breckenridge Pharmaceutical,
`Inc., No. 1:16-cv-00628-SLR (D. Del.), which also involves the ’339
`patent, and (2) Bayer Intellectual Property GmbH, et al. v. InvaGen
`Pharmaceutical Inc., No. 1:16-cv-00064-SLR (D. Del.), which also
`involves the ’339 and ’860 patents. Bayer has asserted the ’339 and
`’860 patents in an additional case, Bayer Intellectual Property GmbH,
`et al. v. Micro Labs Ltd., et al., No. 1:16-cv-00242-SLR (D. Del),
`which has also been consolidated with Case No. Case No. 15-cv-902-
`SLR.
`
` Case No. IPR2017-00042, in which Petitioner has filed a petition for
`inter partes review of the ’860 patent.
`
`
`
`
`
`
`
`Case IPR2017-00041
`Patent No. 7,157,456
`
` Case No. IPR2017-00043, in which Petitioner has filed a petition for
`inter partes review of the ’339 patent.
`
` Pending Application No. 15/069,245 is related to the ’456 patent.
`
`C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))
`
`Patent Owner designates the following counsel:
`
`Lead Counsel:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Back-up Counsel:
`
`Dov P. Grossman (Reg. No. 72,525)
`Williams & Connolly LLP
`
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5812
`Facsimile: 202-434-5029
`
`Galina I. Fomenkova (Reg. No. 72,583)
`Williams & Connolly LLP
`
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5760
`Facsimile: 202-434-5029
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Powers of attorney appointing these attorneys to transact all business in this
`
`proceeding are submitted together with this mandatory notice information.
`
`D. Service Information (37 C.F.R. § 42.8(b)(4))
`
`Counsel for Patent Owner submits the following service information:
`
`
`(i)
`
`Electronic mail address:
`
`
`(ii) Postal mailing address:
`
`dgrossman@wc.com
`gfomenkova@wc.com
`
`
`Dov P. Grossman
`Williams & Connolly LLP
`
`
`
`
`
`
`
`
`
`Case IPR2017-00041
`Patent No. 7,157,456
`
`725 Twelfth Street, N.W.
`Washington D.C. 20005
`
`(iii) Hand-delivery address: Dov P. Grossman
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington D.C. 20005
`
`
`
`(iv) Telephone number:
`
`Facsimile number:
`
`(v)
`
`
`
`
`
`202-434-5812
`
`202-434-5029
`
`
`Counsel for Patent Owner consents to electronic service by email at:
`
`dgrossman@wc.com and gfomenkova@wc.com.
`
`
`
`Dated: October 28, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
`
`
`/Dov P. Grossman/
`Dov P. Grossman
`Reg. No. 72,525
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington, DC 20005
`Telephone: 202-434-5812
`Facsimile: 202-434-5029
`Email: dgrossman@wc.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-00041
`Patent No. 7,157,456
`
`CERTIFICATE OF SERVICE
`(37 C.F.R. § 42.6(e))
`The undersigned hereby certifies that the document above was served on
`
`
`
`
`
`this 28th day of October, 2016, on the Petitioner by delivering a copy via electronic
`
`mail to the following individuals at the email addresses below:
`
`By: /Dov P. Grossman/
`Dov P. Grossman
`Lead Counsel for Patent Owner
`Registration No. 72,525
`
`Steven W. Parmelee
`Reg No. 31,990
`parmelee@wsgr.com
`
`Michael T. Rosato
`Reg. No. 52,182
`mrosato@wsgr.com
`
`Jad A. Mills
`Reg. No. 63,344
`jmills@wsgr.com
`
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue
`Suite 5100
`Seattle, WA 98104-7036
`P: 206-883-2542
`F: 206-883-2699
`
`
`
`Date: October 28, 2016
`
`